About Nicotinamide N-methyltransferase
Nicotinamide N-methyltransferase (NNMT) is a protein
from Homo sapiens identified by UniProt accession
P40261, 264 residues long.
MolForge cross-references it against 0 known binders and
281 disease associations.
Target properties
| Protein name | Nicotinamide N-methyltransferase |
|---|
| UniProt accession | P40261 |
|---|
| Gene | NNMT |
|---|
| Organism | Homo sapiens |
|---|
| Length | 264 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (281)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.37
- neuroinflammatory disorder · score 0.25
- heel bone mineral density · score 0.15
- platelet count · score 0.13
- monocyte count · score 0.13
- cortical surface area measurement · score 0.12
- monocyte percentage of leukocytes · score 0.11
- cancer · score 0.11
- central nervous system cancer · score 0.11
- mean platelet volume · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P40261-F1 | alphafold | PREDICTED | 96.09 | — |
Amino-acid sequence (264 residues)
MESGFTSKDT YLSHFNPRDY LEKYYKFGSR HSAESQILKH LLKNLFKIFC LDGVKGDLLI DIGSGPTIYQ LLSACESFKE IVVTDYSDQN LQELEKWLKK EPEAFDWSPV VTYVCDLEGN RVKGPEKEEK LRQAVKQVLK CDVTQSQPLG AVPLPPADCV LSTLCLDAAC PDLPTYCRAL RNLGSLLKPG GFLVIMDALK SSYYMIGEQK FSSLPLGREA VEAAVKEAGY TIEWFEVISQ SYSSTMANNE GLFSLVARKL SRPL
Explore Nicotinamide N-methyltransferase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets